Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13545706 | 0.85 | USP30 (0.38) | ALDH1A1CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL3616009 | 0.82 | CHRM3 (0.59) | ALDH1A1CHRM3CHRM2CHRM1CYP2D6 | |
| SCHEMBL3608809 | 0.78 | CHRM3 (0.43) | ALDH1A1CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL5243856 | 0.74 | CHRM3 (0.43) | ALDH1A1CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL3620063 | 0.74 | CNR1 (0.39) | ALDH1A1CHRM3CHRM2CHRM1LMNA | |
| SCHEMBL3618915 | 0.71 | CNR1 (0.42) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL3620974 | 0.71 | CHRM3 (0.62) | ALDH1A1CHRM3CHRM2CHRM1 | |
| SCHEMBL13545705 | 0.70 | CHRM3 (0.53) | ALDH1A1CHRM3CHRM2CHRM1 | |
| SCHEMBL1014405 | 0.70 | FUCA1 (0.53) | — | |
| SCHEMBL3621284 | 0.66 | CHRM3 (0.49) | ALDH1A1CHRM3CHRM2CHRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-21 | — | — | US | claimed |
| EP-1828174-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-09-05 | — | — | EP | claimed |
| WO-2006054162-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-05-26 | — | — | WO | claimed |
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-21 | — | — | US | disclosed |
| EP-1828174-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006054162-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | ALDH1A1 1337/4885CHRM3 1/4885CHRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.